Every 8-K that CANNAPHARMARX INC (CPMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CPMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CPMD filings page.
CannaPharmaRX, Inc. reported that director Rick Orman resigned from its Board of Directors effective immediately on January 8, 2026. The company states that his resignation did not result from any dispute or disagreement with the company or the Board regarding operations, policies, or practices.
The company also noted that on January 12, 2026, it issued a press release providing corporate updates and outlining its 2026 growth strategy, which has been furnished as an exhibit to this report.
CannaPharmaRX, Inc. reports that the BC Securities Commission has revoked its failure-to-file cease trade order, effective December 12, 2025, after the company completed its previously delinquent Canadian and U.S. filings. The order had stemmed from missing annual financial statements and related disclosures for the year ended December 31, 2022.
Despite this regulatory step, the company highlights substantial doubt about its ability to continue as a going concern. It reports a working capital deficiency of $27,009,769 and related party debt of $10,762,898 with accrued interest of $3,248,127 as of September 30, 2025. Management’s plan includes negotiating debt restructurings, seeking additional working capital, ramping cannabis production at its Cremona, Alberta facility beyond the current six of ten operating grow rooms, and expanding into European markets such as Germany and Israel, supported by a planned EU-GMP certification application.
CannaPharmaRX, Inc. entered into letter agreements that set out payment schedules to address outstanding amounts owed to two significant debtholders. The company states that these schedules are intended to manage existing debt, avoid additional defaults, and still retain capital to grow operations and deliver product. The agreements and their terms had already been described in the company’s quarterly report for the period ended June 30, 2025, but the actual schedule documents were mistakenly omitted. This report is being used to file those repayment schedule agreements as exhibits so they are formally included in the public record.